CAMP4 Therapeutics(CAMP.US)

Last Updated 19:00:00 ET
longbridge loading

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga_article·
US
YDES
-3.97%
US
HITI
-2.53%
US
PRFX
-10.81%
benzinga_article·
US
YDES
-3.97%
US
HITI
-2.53%
US
PRFX
-10.81%

This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

benzinga_article·
US
CAMP
-0.24%
US
XOM
-2.08%
US
EXR
+0.98%
benzinga_article·
US
CAMP
-0.24%
US
XOM
-2.08%
US
EXR
+0.98%

Camp4 Therapeutics shares are trading higher after Chardan Capital initiated coverage on the stock with a Buy rating and announced a $6.5 price target.

benzinga_article·
US
CAMP
-0.24%
benzinga_article·
US
CAMP
-0.24%

CAMP4 Therapeutics Corporation (CAMP) Receives a New Rating from Chardan Capital

Tip Ranks·
US
CAMP
-0.24%
Tip Ranks·
US
CAMP
-0.24%

CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy

Tip Ranks·
US
CAMP
-0.24%
US
BIB
+0.08%
US
XBI
+0.95%
Tip Ranks·
US
CAMP
-0.24%
US
BIB
+0.08%
US
XBI
+0.95%

Buy Rating Reaffirmed on CAMP4 as CMP-002 Advances Toward 2026 SYNGAP1 Trial and Strong Cash Runway Extends Into 2028

Tip Ranks·
US
CAMP
-0.24%
US
BIB
+0.08%
US
IBB
+0.12%
Tip Ranks·
US
CAMP
-0.24%
US
BIB
+0.08%
US
IBB
+0.12%

CAMP4 Reports Net Loss Of $18 Mln In Q1; Advances CMP-002 For SYNGAP1-related Disorders

nasdaq·
US
CAMP
-0.24%
US
BIB
+0.08%
US
BBH
-0.24%
nasdaq·
US
CAMP
-0.24%
US
BIB
+0.08%
US
BBH
-0.24%
© 2026 Longbridge｜Disclaimer